Sequential Use of Nitazoxanide (NTZ) as a Salvage Therapy in Patient with Recurrent Mild to Moderate Clostridium Difficile Infection (CDI): A Prospective, Open-label, Randomized Clinical Trial

2010 ◽  
Vol 105 ◽  
pp. S142 ◽  
Author(s):  
Patrick P Basu ◽  
Niraj James Shah ◽  
Nithya Krishnaswamy ◽  
Ramya Korapati ◽  
Chris Tang ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Clostridium Difficile ◽  
Randomized Clinical Trial ◽  
Clostridium Difficile Infection ◽  
Salvage Therapy ◽  
Open Label

Randomized Clinical Trial in Clostridium difficile Infection Confirms Superiority of Fidaxomicin Over Vancomycin

2010 ◽  
Vol 139 (1) ◽  
pp. e17 ◽  
Author(s):  
Stuart Johnson ◽  
Derrick W. Crook ◽  
Oliver A. Cornely ◽  
Kevin P. High ◽  
Mark Miller ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Clostridium Difficile ◽  
Randomized Clinical Trial ◽  
Clostridium Difficile Infection

scholarly journals Randomized clinical trial to evaluate the effect of fecal microbiota transplant for initial Clostridium difficile infection in intestinal microbiome

PLoS ONE ◽  
2017 ◽  
Vol 12 (12) ◽  
pp. e0189768 ◽  
Author(s):  
Adrián Camacho-Ortiz ◽  
Eva María Gutiérrez-Delgado ◽  
Jose F. Garcia-Mazcorro ◽  
Soraya Mendoza-Olazarán ◽  
Adrián Martínez-Meléndez ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Clostridium Difficile ◽  
Randomized Clinical Trial ◽  
Clostridium Difficile Infection ◽  
Fecal Microbiota ◽  
Intestinal Microbiome ◽  
Fecal Microbiota Transplant

751a Opt-80 Versus Vancomycin in Clostridium difficile Infection: Results of a Randomized Clinical Trial

2009 ◽  
Vol 136 (5) ◽  
pp. A-115 ◽  
Author(s):  
Mark Miller ◽  
Kathleen M. Mullane ◽  
Karl Weiss ◽  
Arnold Lentnek ◽  
Yoav Golan ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Clostridium Difficile ◽  
Randomized Clinical Trial ◽  
Clostridium Difficile Infection

Melatonin reduces the mortality of severely-infected COVID-19 patients

2021 ◽  
Vol 4 (4) ◽  
pp. 613-616
Author(s):  
Dun-Xian Tan ◽  
Russel J Reiter
Keyword(s):  
Clinical Trial ◽  
Clinical Trials ◽  
Mortality Rate ◽  
Randomized Clinical Trial ◽  
Control Group ◽  
Mortality Reduction ◽  
Single Center ◽  
Open Label ◽  
Melatonin Treatment ◽  
The World

SARS-CoV-2 has ravaged the population of the world for two years. Scientists have not yet identified an effective therapy to reduce the mortality of severe COVID-19 patients. In a single-center, open-label, randomized clinical trial, it was observed that melatonin treatment lowered the mortality rate by 93% in severely-infected COVID-19 patients compared with the control group (see below). This is seemingly the first report to show such a huge mortality reduction in severe COVID-19 infected individuals with a simple treatment. If this observation is confirmed by more rigorous clinical trials, melatonin could become an important weapon to combat this pandemic.

Sign in / Sign up

Export Citation Format

Share Document